ITEM METADATA RECORD
Title: Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients
Authors: Morales, Leilani ×
Timmerman, Dirk
Neven, Patrick
Paridaens, Robert #
Issue Date: Jan-2006
Publisher: Blackwell Scientific Publications
Series Title: International Journal of Gynecological Cancer vol:16 issue:2 pages:515-517
Abstract: The estrogenic activity of tamoxifen on the uterus increases the risk of developing benign and malignant uterine pathologies in breast cancer patients receiving this drug. This has led to gynecological interventions specifically in symptomatic women to exclude malignant disease. Given this known side effect associated with tamoxifen therapy, newer endocrine therapies such as the third-generation aromatase inhibitors have been compared to tamoxifen also in terms of their uterine effects. To date, studies that have directly compared the uterine effects of tamoxifen with that of aromatase inhibitors generally show that aromatase inhibitors such as anastrozole, letrozole, and exemestane are associated with less uterine pathologies compared to tamoxifen. Furthermore, aromatase inhibitors may even reverse uterine abnormalities induced by tamoxifen. This implies that the absence of a stimulatory effect on the uterus would be one of the benefits gained with aromatase inhibitor therapy and may decrease or even obviate the need for gynecological interventions.
URI: 
ISSN: 1048-891X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
Basic Research in Gynaecology Section (-)
Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy

 




All items in Lirias are protected by copyright, with all rights reserved.